Literature DB >> 31560084

[Monoclonal antibodies].

J Mössner1, A Neubauer2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31560084     DOI： 10.1007/s00108-019-00680-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  10 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Margaret H Collins; Yehudith Assouline-Dayan; Larry Evans; Sandeep Gupta; Alain M Schoepfer; Alex Straumann; Ekaterina Safroneeva; Michael Grimm; Heather Smith; Cindy-Ann Tompkins; Amy Woo; Robert Peach; Paul Frohna; Sheila Gujrathi; Darryl N Penenberg; Caiyan Li; Gregory J Opiteck; Allan Olson; Richard Aranda; Marc E Rothenberg; Evan S Dellon
Journal:  Gastroenterology       Date:  2018-11-02       Impact factor: 22.682

3.  Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

Authors:  Johann S de Bono; Nicole Concin; David S Hong; Fiona C Thistlethwaite; Jean-Pascal Machiels; Hendrik-Tobias Arkenau; Ruth Plummer; Robert Hugh Jones; Dorte Nielsen; Kristian Windfeld; Srinivas Ghatta; Brian M Slomovitz; James F Spicer; Jeffrey Yachnin; Joo Ern Ang; Paul Morten Mau-Sørensen; Martin David Forster; Dearbhaile Collins; Emma Dean; Reshma A Rangwala; Ulrik Lassen
Journal:  Lancet Oncol       Date:  2019-02-08       Impact factor: 41.316

4.  Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.

Authors:  Fei Li Kuang; Fanny Legrand; Michelle Makiya; JeanAnne Ware; Lauren Wetzler; Thomas Brown; Tamika Magee; Brent Piligian; Pryscilla Yoon; Jamie H Ellis; Xiaoping Sun; Sandhya R Panch; Astin Powers; Hawwa Alao; Sheila Kumar; Martha Quezado; Li Yan; Nancy Lee; Roland Kolbeck; Paul Newbold; Mitchell Goldman; Michael P Fay; Paneez Khoury; Irina Maric; Amy D Klion
Journal:  N Engl J Med       Date:  2019-04-04       Impact factor: 91.245

5.  Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Kohei Shitara; Maria Di Bartolomeo; Sara Lonardi; Salah-Eddin Al-Batran; Eric Van Cutsem; David H Ilson; Maria Alsina; Ian Chau; Jill Lacy; Michel Ducreux; Guillermo Ariel Mendez; Alejandro Molina Alavez; Daisuke Takahari; Wasat Mansoor; Peter C Enzinger; Vera Gorbounova; Zev A Wainberg; Susanna Hegewisch-Becker; David Ferry; Ji Lin; Roberto Carlesi; Mayukh Das; Manish A Shah
Journal:  Lancet Oncol       Date:  2019-02-01       Impact factor: 41.316

6.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Authors:  Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum
Journal:  N Engl J Med       Date:  2019-06-09       Impact factor: 91.245

7.  Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Authors:  Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

8.  Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.

Authors:  Chang-Yi Wang; Wing-Wai Wong; Hung-Chin Tsai; Yen-Hsu Chen; Be-Sheng Kuo; Shugene Lynn; Jana Blazkova; Katherine E Clarridge; Hsiao-Wen Su; Chia-Ying Lin; Fan-Chen Tseng; Annie Lai; Fu-Hung Yang; Chen-Han Lin; William Tseng; Hsiao-Yi Lin; Connie L Finstad; Flossie Wong-Staal; Carl V Hanson; Tae-Wook Chun; Mei-June Liao
Journal:  N Engl J Med       Date:  2019-04-18       Impact factor: 91.245

9.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

10.  Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Shuzhen Liu; Bingshu Chen; Samantha Burugu; Samuel Leung; Dongxia Gao; Shakeel Virk; Zuzana Kos; Wendy R Parulekar; Lois Shepherd; Karen A Gelmon; Torsten O Nielsen
Journal:  JAMA Oncol       Date:  2017-11-09       Impact factor: 31.777
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.